yanimo respimat 2,5 mikrogrami/2,5 mikrogrami šķīdums inhalācijām
boehringer ingelheim international gmbh, germany - tiotropium, olodaterolum - Šķīdums inhalācijām - 2,5 μg/2,5 μg
spiolto respimat 2,5 mikrogrami/2,5 mikrogrami inhalācijas šķīdums
boehringer ingelheim international gmbh, germany - tiotropium, olodaterolum - inhalācijas šķīdums - 2,5 μg/2,5 μg
striverdi respimat 2,5 mikrogrami inhalācijas šķīdums
boehringer ingelheim international gmbh, germany - olodaterols - inhalācijas šķīdums - 2,5 µg
trixeo aerosphere
astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
bevespi aerosphere
astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - plaušu slimība, hroniska obstruktīva - formoterol un glycopyrronium bromide - bevespi aerosphere ir norādīts, kā tehniskās apkopes bronchodilator ārstēšana, lai mazinātu simptomus pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).